Company news

Cardiol Therapeutics Inc. news in 2026

Cardiol Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

November 3, 2026

Ellis Martin Report: Cardiol Therapeutics (CRDL) CEO David Elsley Discusses Phase III MAVERIC and What Comes Next for CardiolRx

October 8, 2026

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx(TM)'s Efficacy

September 23, 2026

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

September 16, 2026

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

September 10, 2026

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

August 5, 2026

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

July 14, 2026

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

July 9, 2026

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

June 25, 2026

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4: 30 p.m. EDT

June 23, 2026

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

May 14, 2026

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

May 7, 2026

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

April 28, 2026

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

April 14, 2026

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

April 1, 2026

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

February 25, 2026

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

February 10, 2026

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

January 23, 2026

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

January 16, 2026

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

January 16, 2026

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

January 13, 2026

Decks in 2026